In this first of two CE Concepts BriefCases in this series, expert faculty will discuss how to assess current surveillance practices and apply strategies to identify individuals at risk for VHL. Through realistic clinician-patient interactions and data-driven insights, this innovative format connects evidence to real-world patient journeys, equipping clinicians to confidently recognize early signs of VHL and implement effective surveillance to support timely detection and improved outcomes.
In the third of this 3-part CEC Oncology BriefCase series, expert faculty and a patient advocate delve into interprofessional strategies for preventing and mitigating adverse events while collaboratively promoting QoL for patients being treated for HER2-negative MBC.
In the second of this 3-part CEC Oncology BriefCase series, expert faculty review emerging data on ADC therapy for HER2-negative MBC, describe therapy selection and treatment sequencing rationale, and hear from a patient advocate about patient concerns regarding this new therapy option.
In the first of this 3-part CEC Oncology BriefCase series, expert faculty introduce clinicians to ADC therapy for HER2-negative MBC and hear from a patient advocate about patient concerns regarding this new therapy option.
